---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-22-000015"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2022-01-26T23:59:59+00:00"
generated_at: "2026-06-27T15:26:41.773441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evolus reports Q4 preliminary revenue $34.7M (+68% YoY), guides 2022 revenue $143-150M

## Summary
- Q4 2021 preliminary net revenue $34.7M, up 68% YoY; full-year 2021 revenue $99.7M, up 76% YoY.
- Cash position $146.3M at Dec 31, 2021; expects sufficient funding through cash flow breakeven.
- 2022 net revenue guidance $143-150M (43-50% growth); adjusted gross margin 58-61% full year, improving to 68-71% in Q4.
- Plans to initiate Phase 2 'extra strength' Jeuveau trial in Q1 2022; European Nuceiva launch in Q3 2022.
- Added 1,400+ new accounts in 2021; consumer loyalty program reached 270,000+.

## SEC filing metadata
- accession: 0001570562-22-000015
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2022-01-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000015/0001570562-22-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000015/eols-20220126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-22-000015
- JSON: https://secwatch.observer/filing/0001570562-22-000015.json
- Plain text: https://secwatch.observer/filing/0001570562-22-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.